Biomarkers in colorectal cancer: Current clinical utility and future perspectives

doi:10.12998/wjcc.v6.i15.869

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10639)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1050

WORD

272

HTML

7031

Figures (1-1)

224

Tables (1-2)

183

Sum=8760

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

859

Download

1020

Sum=1879

Dec 6, 2018 (publication date) through Jul 23, 2024

Times Cited of This Article

Times Cited (98)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Cases. Dec 6, 2018; 6(15): 869-881
Published online Dec 6, 2018. doi: 10.12998/wjcc.v6.i15.869

Table 2 Examples of epigenetic biomarkers for colorectal cancer

Epigenetic markers
Methylated genes/loci
p14 ARF, p15 INK 4b, p16 INK4a	Cell cycle regulation
hMLH1, MGMT	DNA repair system; progression from adenoma to cancer
DAPK	Apoptosis
THBS1	Angiogenesis inhibition
SPARC	Lymphovascular invasion, metastasis
TIMP3	Metastasis suppression
CDH1, CDH13	Cell adherence
Methylation biomarkers
VIM, SEPT9, SFRP2	Biomarkers for CRC and as DNA-based colon cancer screening tests
TWIST1, IGFBP3, GAS7, ALX4, SDC2	Higher methylation levels in CRC compared to normal subjects (promising diagnostic biomarkers)
Candidate biomarkers
Methylated UGT1A1	Affects irinotecan treatment (in vitro)
Methylated DYPD, UMPK, and SPARC	Affect 5-FU treatment (in vitro)
TFAP2E	No responsiveness to oxaliplatin, irinotecan, and 5-FU

CRC: Colorectal cancer; FU: Fluorouracil.

Citation: Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases 2018; 6(15): 869-881
URL: https://www.wjgnet.com/2307-8960/full/v6/i15/869.htm
DOI: https://dx.doi.org/10.12998/wjcc.v6.i15.869